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Abstract
Background: Although tardive dyskinesia (TD) is most commonly defined as a movement disorder caused by chronic exposure to dopamine-receptor-blocking
drugs (DRBDs), it has also been thought to result from exposure to some non-DRBDs.
Methods: We critiqued many reviews making the association between non-DRBDs and a TD-like syndrome and almost all case reports. We checked whether
cases met criteria for the diagnosis of TD-like syndrome and whether DRBDs had been excluded.
Results: We found that both tricyclic antidepressants and selective serotonin reuptake inhibitor antidepressants may unmask or exacerbate TD after prior
exposure to or with concurrent use of DRBDs. We found support for its existence outside of this context to be extremely weak.
Discussion: There is little evidence that drugs other than DRBDs by themselves cause a TD syndrome; most reported cases appear to occur as a result of a
‘‘priming’’ effect induced by a DRBD, which is later unmasked.
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Introduction
The association between long-term exposure to DRBDs and
persistent, usually irreversible, movement disorders is well accepted,
but whether chronic exposure to drugs not known to block dopamine
receptors can also cause a similar syndrome is unclear. We reviewed
the reports making this association to determine if such an association
is likely to exist.
There is no single consensus definition of tardive dyskinesia (TD).
The definition has been revised within the discipline of psychiatry with
each edition of the Diagnostic and Statistical Manual of Mental
Disorders, the standard reference for the diagnosis of psychiatric
disorders. The most recent edition, (DSM-V), published in 2013,
defines TD as ‘‘involuntary athetoid or choreiform movements lasting
at least a few weeks, developing in association with the use of a
neuroleptic medication for at least a few months, and persisting
beyond 4–8 weeks’’.1 This is the most often used definition. Use of this
definition would obviate the need for this paper; however, a syndrome
with a similar phenomenology has been ascribed to non-dopamine
receptor blocking drugs (DRBDs) and is considered to be a form of
TD.2–7 Cornett et al.7 in their review used the DSM-V definition, but
extended potential etiologic drugs to include non-DRBDs.
It is important to note that in the literature the term ‘‘TD’’ is used
both as an umbrella term to include a variety of movement disorders
associated with long term use of neuroleptics, including dystonia and
akathisia, as well as a specific, oral–buccal–lingual choreo-athetoid
movement disorder, typically seen after long-term DRBDs.8 In this
manuscript, we will use the term TD to include all the choreo-athetoid,
stereotypic movements and limit this report to that subset of tardive
syndromes, excluding other tardive syndromes such as akathisia, tics,
and dystonia. The great majority of reports on non-DRBD-induced
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TD pertain to choreo-athetoid movements; therefore, this is not a
significant restriction. The second largest number of reports is on
akathisia, which is a not uncommon acute side effect of selective
serotonin reuptake inhibitors (SSRIs), and confounds our ability to
distinguish an acute from a tardive syndrome. The other syndromes
are much less commonly described in publications.
The difficulties in associating movement disorders with parti-
cular medications other than DRBDs include the rarity of the
problem, the often unverifiable medical history, and the occurrence
of similar movement disorders with no clear etiology in an untreated
population.
In the early years after neuroleptics were introduced, the choreo-
athetoid and stereotypical movements were recognized, but it was
not clear whether they were associated with the treatment or the
underlying diseases9. The concurrence of a variety of movement
disorders with schizophrenia, in particular, and other mental illnesses
had been recognized for many decades prior to the development of
antipsychotic and antidepressant drugs, which confounded the inter-
pretation of the newly developing movement disorder.10,11 This was
due to the reasons just listed, plus the current lack of diagnostic clarity.
The recognition that TD was a diagnostic entity secondary to neuro-
leptics was due to the rapidly increasing number of cases identified as
drug use increased, making the association undeniable, after early
skepticism.
In evaluating the association between dyskinesias and the possibility
of non-DRBD etiologies, the situation is quite similar to that of the
early days of neuroleptic use. Isolated cases were reported and the
association with particular drugs was suspected, but not provable.
However, with neuroleptics, once the syndrome was identified it
became clear that the association was robust. This is not the case with
non-DRBDs. While many cases have been reported, the majority
are not convincing. Their occurrence appears to be quite rare, mak-
ing alternative explanations, such as inadequate history and non-
diagnosed concurrent, but unrelated, primary neurological disorders,
more likely. Finally, psychogenic (functional) movement disorders may
be enriched in populations exposed to psychoactive drugs, and can
be difficult to diagnose reliably. As early as 1992, Fishbain et al.12
suggested the possibility that non-DRBD TD-like disorders likely




A 70-year-old male had prominent oral–buccal–lingual dyskinesias.
He was nearly edentulous and had been on risperidone and quetiapine
in recent years. He and his wife reported that his mouth movements
had not changed since they had first appeared over 40 years ago, prior
to losing any teeth or having taken any psychiatric medications. While
this case appears to be a ‘‘classic’’ case of TD, exacerbated by the
absence of teeth, the history does not support this diagnosis. Unfor-
tunately, there is no way to check the history.
Case 2
A 79-year-old retired, female psychiatric registered nurse was
evaluated for tremors and falls. She had a gait abnormality ascribed to
vascular disease, although without a history or magnetic resonance
imaging evidence of a stroke. She was found, coincidentally, to have
classic TD signs of chewing movements and tongue writhing severe
enough to cause tongue ulcers. She had been taking paroxetine for
over 15 years, and tricyclic antidepressants (TCAs) prior. She had
also taken prochlorperazine for only a few days at a time during
her chemotherapy cycles for chronic lymphocytic leukemia. She had
never been on other DRBDs. The movements postdated her use of
prochlorperazine.
These two cases are our own and are similar to those in the
literature ascribed to antidepressant medications. The first case might
be a case of spontaneous oral facial dyskinesias,13,14 which, if it occur-
red after exposure to an antidepressant, might have been considered
another case, or our history is incomplete. The second case had only
minimal exposure to a DRBD, and might have been included in most
of the reviews discussed in detail below.
Methods
We used the definition of TD employed by a recent review,7 even
though old case reports relied on earlier DSM editions. Our review
was not complete due to difficulty accessing old articles. We assessed
whether cases were on concurrent DRBDs, had known exposure to
DRBDs, had statements specifically excluding a history of DRBD use,
the time of onset of the movement disorder with respect to the non-
DRBD, and the duration of the movement once the DRBD was
discontinued.
The authors reviewed most, but not all articles (see below), in
PubMed and Web of Science under the search headings TD, move-
ment disorders, extrapyramidal syndrome, and drugs either by class
(antidepressants, SSRIs, TCA, anxiolytics, sedatives, hypnotics, anti-
convulsants/anti-epileptics, antihistaminic, amphetamine, anticholi-
nergic, stimulants) or individual names (phenytoin, fluoxetine, lithium,
etc.). We reviewed over 300 articles that were reviews, small series,
or case reports. These were difficult to review since they were old, and
thus without abstracts on PubMed, often letters to the editor, and also
without abstracts for quick review. Thus, the review was systematic
and relatively, but not fully, comprehensive.
Results
The striking feature of most review articles is their failure to use
defined criteria for TD in their citations or in their own cases that they
added. In general, most reviews cited previous review articles that
themselves cited cases, or other reviews, many of which cited cases that
did not fit any current definition for a ‘‘TD-like’’ syndrome, that is,
a new movement disorder that persisted for a defined period of time
after the drug was withdrawn. All had dyskinesias, but most lasted for
short periods of time, while on the offending drug, and resolved quickly
when it was removed. Equally importantly, almost all reports included,
with little or no discussion, cases with concurrent or prior exposure to
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DRBDs. Few reports specifically stated that they had excluded a
history of DRBD exposure, or performed an evaluation to exclude a
primary cause for the movement disorder. The following evaluation of
major reports reviewing the topic of TD and non-DRBDs provides
some details.
Cornett et al.7 cite four references for TD. In one,15 the patient
developed acute mandibular dystonia within 2 days of treatment with
fluoxetine; dystonia improved soon after discontinuation. The second
citation listed three cases, one of which had been on DRBDs.16
Neither of the other two cases excluded a history of DRBDs. The third
citation described one case of their own, which had prior DRBD
exposure and mentioned nine other cases, of which one was on
concomitant DRBDs and eight did not meet the criteria for a diagnosis
of TD.3 Clayton et al.4 described one case of their own, which meets
the criteria for inclusion here and 17 other cases,17–28 all of which had
prior DRBD exposure or did not meet criteria for TD. In sum, this
paper lists 32 purported cases of TD induced by antidepressants of
which a single case meets our criteria for non-DRBD-induced TD.
Leo’s5 report was a review with no new cases added. Eight citations
were included for ‘‘TD-like’’ syndromes ascribed to SSRIs. All are
included in other discussions within this paper.3,12,29–34 Fishbain
et al.12 case qualifies under our criteria. None of the others meet the
criteria for non-DRBD-induced TD either because of concurrent or
past DRBD use3,29–33 or failure to exclude a history of DRBD.34 Yassa
et al.27 evaluated 50 patients hospitalized for depression and found
three cases of ‘‘TD,’’ one on amoxapine, a DRBD, and two on doxepin,
but there was no mention of possible prior use of DRBD. Onset was
abrupt with doxepin and resolved quickly when the drug was stopped.
The two cases without clear DRBD exposure did not meet clinical
criteria for TD.
A chapter in an e-textbook of neurology on TD cites three references
in support of non-DRBDs causing TD.2 One report describes a patient
on concurrent DRBDs.35 One undoubtedly had been on neuroleptics
prior to receiving clozapine for longstanding psychosis, and thus had
prior DRBD use,36 although not explicitly stated. The third citation is a
review paper, which described 12 cases, 10 of whom had DRBD
exposure, an 11th with cerebellar disease, etiology unstated, and one
without stated explicit exclusion of prior DRBD exposure.37
In a large review by Hawthorne and Caley,6 18 cases are cited, eight
of whom were taking or had taken DRBDs.38–45 An additional case
was a 15-month-old child with stereotypies and repetitive movements
prior to treatment and most others without an adequate description of
previous drug therapy to exclude DRBDs. In only three cases was it
clearly stated that no known DRBD exposure existed,46–48 and the
movements persisted for a few weeks after drug discontinuation in one
case, and less than 4 months in another case.46 One of the cases with
no DRBD history,47 however, had suffered Traumatic Brain Injury
(TBI) requiring surgical evacuation of intraparenchymal hematomas.
In five cases neuroleptic exposure was not commented upon49 or the
clinical picture was not compatible with the definition of TD.49–52
Lee and Nam40 cited five reports of TD induced by SSRI and added
a single case of their own. Their case had prior DRBD use. One report
described two cases, neither of which meet the criteria for TD.53
Another did meet the criteria but did not exclude DRBDs.34 One
excluded DRBD history and still met the criteria for TD but speci-
fically doubted that the SSRI was causal (see quote above).12 One
report54 had acute akathisia and no dyskinesias. Their fifth citation,
which described three of their own cases, had one with prior DRBD
use and two in which prior use was not excluded.16
In a review of SSRI-induced movement disorders, 12 cases of
dyskinesia were noted in their database, 10 of whom had DRBD
exposure and one had prior cerebellar dysfunction.37 Whether the
12th specifically denied DRBD use is unstated. All were women.
The paper also cited 34 ‘‘sertraline-induced dyskinesia’’ cases reported
to Pfizer, of whom five were taking neuroleptics, two had a prior
movement disorder, and no data were available for the others. Eli Lilly
reported 76 cases related to fluoxetine, but no data for DRBD were
included. This paper also added six other SSRI-associated cases, of
which one53 was not TD; the others are in reference citations.16,30,34
Another similar review on SSRIs5 reported cases on concomitant
DRBDs or history of DRBD use;3,30 non-TD cases;3,29,31,33 failure to
exclude a history of DRBDs;34 an unknown number of dyskinesia cases
included in a report of 15 cases with a variety of extrapyramidal
disorders, of whom five were on concurrent DRBD, with no infor-
mation about prior use of DRBD provided for the others.32 One
case,12 noted above, did meet our criteria.
There is a single report of buspirone causing a TD-like syndrome in
one patient. This patient had primary torticollis, then developed classic
TD on a DRBD that worsened with buspirone,55 and therefore does
not meet criteria.
Fann et al.18 cites reports of purported TCA-induced TD cases.
Some were on concomitant DRBD;19,27,28 some had prior use of
DRBDs;18,22 some did not meet clinical criteria for TD;24,26,27 some
did not specifically mention history of possible DRBDs or thought it
partly due to primary brain disease.17 The eleventh report,17 which
included one case of their own that meets our criteria for TD-like and
no DRBD exposure, also referenced 17 others, who were all patients
with DRBD use prior to onset.4 Thus, there was one case meeting our
criteria from 10 reports citing 31 purported cases.17
Another review56 of purported SSRI-induced TD cases cited cases
that were on DRBDs30,32 or had taken DRBDs,3,29,31,56 but also
referred to four that did not have TD23,53,56,57 and one case in which
prior DRBD was not excluded;34 there were five cases17 in which
DRBDs are not clearly excluded and in which the movements were
thought due primarily to primary brain disorder. Thus, this paper
cited a single case of SSRI-induced TD not clearly exposed to DRBDs.
A second review on TCA-induced TD reported one case with prior
DRBD,18 one with concurrent DRBD,19 one case that did not exclude
DRBD use,57 and two cases that were not TD.23,24 This paper also
noted cases of dyskinesia reported to the Food and Drug Admi-
nistration of adverse event reports, of which there were 89 cases.
The authors estimated the incidence of any movement-disorder-
related adverse event at less than one per 1,000 among SSRI users
(no time period provided). This review also cited other reviews
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previously discussed.5,37 In one, five cases were reported, with
problems as noted above.17
The proper documentation of TD criteria with drugs other than
antidepressants is even less detailed, and the same limitations presented
above, such as improper diagnosis, lack of differentiation between
other hyperkinetic syndromes and TD, and incomplete documentation
of associated drug use and drug exposure history, are frequently
observed. For instance, Cornett et al. 7 cite anti-epileptic drugs (AEDs).
In reality, one reference cited describes a link between tics and
carbamazepine and lamotrigine. 58 The only other AED in their report
is phenytoin. Dyskinesias associated with phenytoin in the report
were acute or associated with other signs of phenytoin toxicity, 59–63
a well-known disorder unrelated to TD.
Other reports on dyskinesias and phenytoin share the same
characteristics and were either acute, after therapy initiation, or drug
increase, or present during episodes of intoxication.64,65 Two cases
of dyskinesias reported with gabapentin did not fulfill the criteria
for TD.66 Carbamazepine-induced dyskinesias were reported due
to intoxication67 or concomitant use of lithium.68 Interestingly, one
study found that co-administration of carbamazepine and a second-
generation antipsychotic increased the risk of movement disorders.69
In a study, 201 patients with epilepsy were evaluated by a movement
disorders specialist for the presence of movement disorders. Postural
tremor was the most common finding, observed in 89 patients, fol-
lowed by parkinsonism in nine, dystonia in four, and tics in two. There
were no reports of TD.70
Although retrospective in nature and performed in 1999, another
study involving five movement disorders center identified 100 patients64
who fulfilled the diagnosis of a tardive syndrome, of whom 72 had TD.
Either AEDs, antihistamines, anticholinergics, or amphetamines were
implicated as the causative agent in those cases.71
Reports of TD caused by antihistamines,72–74 anticholinergics,75–77
and amphetamines78 suffer from the same shortcomings as described
for those caused by antidepressants. In a report of two cases of
orofacial dyskinesias and the use of antihistaminic decongestants, one
case had been exposed to fluphenazine and the other to bultalbital and
chlordiazepoxide.72 Therefore, the latter case may not be DRBD-
related. Clark et al.73 described a case of head rolling, lip-licking, and
athetoid tongue movements in a 74-year-old female using daily
hydroxyzine for 7.5 months. The patient, however, had intermittently
used phenothiazine for nausea previously and was also using doxepin.
Lastly, a case of oromandibular dystonia in a 53 year old was attri-
buted to daily use of cetirizine for 7 years. Discontinuation of the drug
did not lead to improvement.74 Although there is a clear temporal
association, a causal relationship is hypothetical.
A few reports often used the term ‘‘dyskinesia,’’ in isolation, without
using the term TD.3,79 However, review articles citing these reports
frequently then classified the case report as a TD-like syndrome, which
was based entirely on the phenomenology of the movements, and not
the temporal relationship between the movements and the implicated
drug, time of onset of the movements, or duration after stopping the
presumed offending agent. The striking feature in most review articles
is their failure to use defined criteria for TD before including their
citations. In general, each review article cited previous review articles
that included citations that generally did not fit any current definition
for a ‘‘TS-like’’ syndrome, that is, a new movement disorder that
persisted for a few weeks after the drug was withdrawn.7 Equally
important, almost all reports included, with little or no discussion,
prior exposure to DRBDs, thus suggesting that the non-DRBD
‘‘unmasked’’ rather than caused the disorder. For example, Mander
et al.3 describe one case of their own, previously on DRBDs, and
provide a review of other cases, but include eight cases of non-TD
movement disorders plus one TD case taking high-dose metoclopra-
mide. Thus, all their cases had priming with DRBDs.
Discussion
Reports on TD (see Table 1) in non-DRBDs are primarily isolated
case reports and small series, (mostly one case, and none larger than five),
Table 1. Reports of TD in non-DRBD in the literature
Authors No. of Reported Cases Cases Meeting Criteria
Hawthorne and Caley6 18 0
Lee and Nam40 8 1
Gerber and Lynd37 46 0
Bharucha and Sethi53 9 0
Coulter and Pillans32 15 1
Leo5 8 1
Clayton et al.4 32 1
Cornett et al7 14 0
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the vast majority of which had a history of either prior or concurrent use
of DRBDs, a clinical syndrome that was not compatible with TD, usually
resolving within days of drug discontinuation, or a history of prior use of
DRBD was not excluded. Reviews usually cited previous reviews, which
themselves included cases that did not meet the criteria for a diagnosis of
TD. Only rare cases of TD ascribed to non-neuroleptics had complete
evaluations for other causes of the movements; however, it is unlikely that
many were actually caused by such a disorder.
Many of the reports include patients who had been exposed to
neuroleptics, but not in recent times. There is no consensus criterion
for how long a patient may be off a DRBD and develop a movement
disorder that may be ascribed to the drug. One review stated that
‘‘exposure to DRBD within 1 year prior to the onset of the tardive
syndrome to be causally related.’’2 It is also unclear what it means to
ascribe causality.80 Our interpretation of the data is that DRBDs
generally provide some sort of ‘‘priming’’ effect, which then, on rare
occasion, with the addition of non-DRBD drugs, unmasks ‘‘latent’’
TD. Conversely, a very small subset of patients with a combination of
certain genetic factors could potentially develop TD after exposure to
non-DRBD drugs.81,82
In 1992 Fishabain et al.12 noted, ‘‘The dyskinesia associated with
antidepressants and also with fluoxetine appears to differ from that of
neuroleptics. Antidepressants, including fluoxetine, may exacerbate
rather than cause the pathophysiological process involved in the
dyskinesia.’’ It is possible that non-DRBDs really have extremely weak
dopamine-receptor-blocking properties, below the level of current
detection.
Conclusion
We believe, like Fishbain et al., 12 but now with several more cases
for support, that non-DRBD psychoactive drugs of various types, most
commonly SSRIs and TCAs, unmask or exacerbate a dyskinetic
disorder due to DRBDs via mechanisms not currently understood.
Our interpretation of the data suggests that antidepressants may
increase the risk of clinically identifiable TD in patients who have
taken DRBDs, even in the remote past. It also suggests that TD-like
syndromes in patients never on DRBDs must be an extraordinarily
rare event so that SSRIs, TCAs, and other non-DRBDs should not be
considered causal until other explanations have been excluded.
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